【摘要】 目的探讨丙戊酸镁合并喹硫平治疗反复躁狂发作的长期疗效及安全性.方法将66例各类情感障碍躁狂发作患者分为丙戊酸镁组和丙戊酸镁合并喹硫平组(下称合并治疗组),每组各33例。急性期治疗6周后随访5年。基线及疗效采用倍克-拉范森躁狂量表(BRMS)评定。随访内容包括复发次数,药物剂量,长期疗效及安全性。结果急性期治疗后BRMS减分率丙戊酸镁组为(42±27)%,合并治疗组为(57±24)%,两组间的差异有统计学意义(P<0.05)。5年内躁狂复发次数丙戊酸镁组为(3.3±2.0)次,合并治疗组为(1.9±1.6)次,两组间的差异有统计学意义(P<0.01);抑郁复发次数丙戊酸镁组为(1.8±2.0)次,合并治疗组为(1.9±1.8)次,两组间的差异无统计学意义(P>0.05)。合并治疗组的丙戊酸镁剂量明显低于单用丙戊酸镁组(P<0.01)。两组总体不良反应的差异无统计学意义。结论丙戊酸镁合并喹硫平维持治疗情感障碍可减少躁狂复发率,且安全性较高。更多还原

【Abstract】 Objective The study was to explore the effectiveness and safety of chronic combination treatment of magnesium valproate with quetiapine on recurent mania.Method All 66 affective disorder patients with mania-onset were randomly assigned to receive magnesium valproate(n=33),and magnesium valproate with quetiapine(n=33),In acute phase treatment of 6 weeks after 5 years.At baseline,the symptom was evaluated with the Bech-Rafaelsen Manin Rating Scale(BRMS).The drug dosage,times of relapse,effectsand safety was compared among the three groups.Results After the acute therapy,the reductions in BRMS score were(42±27)% in magnesium valproate group,(57±24)% in combination group,respectively,with significant differences between the two groups(P<0.05).At followed-up 5 years,mania relapse times was significantly less in combination group than that in magnesium valproate group(mean times of 1.9±1.6,3.3±2.0,P<0.01);depression relapse times was no differences in both groups(mean times of 1.8±2.0,1.9±1.8,P>0.05).The mean dosage of single drug in combination groups was significantly lower than that in magnesium valproate(P<0.01).There were no significantly statistic differences on side-effects two groups.Conclusion It is suggested that the efficacy of combination therapy of magnesium valproate with quetiapine on mania be better than monotherapy with magnesium valproate with the same safety.更多还原